Neo-adjuvant chemotherapy in NSCLC
|
|
- Agnes Floyd
- 6 years ago
- Views:
Transcription
1 SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon 108,070 49,960 Breast 184,450 40,930 Prostate 186,320 28,660 Total 478, ,550 Lung 215, ,840 Jemal, C Cancer J Clin 2008; 58: 71 Lung Cancer Stage Distribution at Time of Diagnosis Peter Jennings Stage III 25% Stage IV 45% Stage I/II Unstaged 14% ational Cancer Institute: SEER Cancer Statistics Review,
2 ISLC Staging Project: Proposed Changes 6th Edition Descriptor Current definition M1 (contralateral lung) M1a IV IV IV IV 5 Goldstraw P et al. J Thorac ncol. 2007;2: Proposed T/M Stage Based on Proposed T/M Definitions T1 ( 2 cm) T1a I II III IIIB T1 (2 3 cm) T1b I II III IIIB T2 ( 5 cm) T2a IB II III IIIB T2 (5 7 cm) T2b II IIB III IIIB T2 (> 7 cm) T3 IIB III III IIIB T3 invasion T3 IIB III III IIIB T4 (same lobe nodules) T3 IIB III III IIIB T4 (extension) T4 III III IIIB IIIB M1 (ipsilateral lung) T4 III III IIIB IIIB T4 (pleural dissemination) M1a IV IV IV IV M1 (distant) M1b IV IV IV IV SCLC: Staging & Prognosis Pathologic Survival Relapse (%) Stage 5 yr (%) Local Distant I T1M IB T2M II T11M IIB T21M T3M 38 III T31M T1-32M 23 Mountain CF. Chest.1997;111: ; Feld R, et al. J Clin ncol. 1984;2: ; Pairolero PC, et al. nn Thorac Surg. 1984;38: ; Martini, Melamed MR. J Thorac Cardiovasc Surg. 1980;30: ; Thomas P, Rubinstein L. nn Thorac Surg. 1990;49: ; Goldstraw P, et al. J Thorac ncol. 2007;2: dvantages of Induction Therapy Improving survival rates with chemotherapy Systemic therapy in a local disease Earlier elimination of micrometastatic disease improved survival Chemotherapy better tolerated before major surgery than after Downstaging of 2 disease survival In vivo evaluation of chemo effects 2
3 dvantages of Induction Therapy Induction Chemotherapy phase III trials Earlier elimination of micrometastatic disease improved survival Chemotherapy better tolerated before major surgery than after Possible downstaging of 2 disease ssessment of chemosensitivity Trial Design Stage n Chemo S9900 RCT IB-II 354 Carbo/paclitaxel LU-22 RCT I-III 519 Platinum-doublet Burdett Meta-analysis I-III 988 Platinum chemo Ch.E.S.T. RCT IB-III 270 Cis/gemcitabine TCH RCT I-III 600 Carbo/paclitaxel merican RCT I-III closed Cis/docetaxel S 9900 S9900 Patient Characteristics IB-III R D M I Z E PCLITXEL CRBPLTI (PCb) x 3 cycles SURGERY SURGERY (n = 167) PCb (n = 168) IB + II 71% 70% CR / PR 3% / 38% R0 resection (ITT) Pneumonectomy Lobectomy 84% 68% 84% 68% Surgical mortality 2.5% 4.5% Mediastinoscopy if L > 1 cm on CT Pisters K, et al. J Clin ncol. 2005;23(16S). bstract Closed 2004 because of adjuvant data Final accrual 354/ ineligible o difference in : Surgical morbidity Pneumonectomy rates Pisters K, et al. J Clin ncol. 2005;23(16S). bstract 7012 and virtual presentation at Vallieres E, et al. Lung Cancer. 2005;49(suppl 2). bstract
4 SWG 9900: Updated Survival Results MRC LU22 / VLT / ERTC PRGRESSI-FREE SURVIVL HR = 0.77 ( ), P = 0.07 (2005: HR = 0.80 [ ], P = 0.14) VERLL SURVIVL HR = 0.81 ( ), P = 0.19 (2005: HR = 0.84 [ ], P = 0.32) IB - III 100% 80% 60% 40% 20% 0% % 80% 60% 40% 20% 0% Months fter Registration Pisters K, et al. J Clin ncol. 2007;25(18S). bstract PCb Induction chemotherapy =258 Chemotherapy: MVP Cisplatin/vinorelbine 45% Cisplatin/gemcitabine 25% Carboplatin/docetaxel 12% Gilligan D, et al. Lancet. 2007;369: =261 76% received all 3 cycles of chemotherapy 4% CR 45% PR Closed early MRC LU22 / VLT / ERTC (n = 261) + Chemo (n = 258) I/IB 15% / 44% 19% / 45% R0 resection Pneumonectomy Lobectomy 79% 28% 50% 81% 23% 56% Surgical Morbidity 43% 38% 2-yr PFS 52% 53% (HR = 0.96) 5-yr S 45% 44% (HR = 1.02) Chemotherapy for Early Stages Trial (Ch.E.S.T.) Stratification IB/II vs. IIB/III (T31 excluding superior sulcus) Mediastinoscopy for ML >1cm R D M IZ TI rm 1: rm 2: Cisplatin/ Gemcitabine F LL WŪ P o difference in : Survival outcome Surgical morbidity Pneumonectomy rates Gilligan D, et al. Lancet. 2007;369: Cisplatin 75 mg/m2, d.1 Gemcitabine 1250 mg/m2 d.1&8, Q 3wks x 3 cycles 1 objective : 3-PFS CLSED ERLY ccrual 270 / 700 Scagliotti, SC 2008,#
5 Ch.E.S.T PFS: Subset analysis by stage only Chemotherapy + Stage IB-II (n) Median PFS (yrs) yr PFS 56% 50% Stage IIB-III (n) Median PFS (yrs) yr PFS (95% CI) 36% (24%-49%) 55% (42%-67%) Log-rank p-value = Ch.E.S.T Progression-Free Survival Events Median PFS (yrs) 3-yr PFS only (=141) 55% % Log-rank p-value* CT+ (=129) 49% % Hazard ratio 95% CI p-value** 0.71 (0.50, 0.99) Pts at risk at years only: CT+: * unadjusted treatment 95 p-value **global 52 model 33 p-value Ch.E.S.T S: Subset analysis by stage only Chemotherapy + Stage IB-II (n) Median S (yrs) 3-yr S 70% 65% Stage IIB-III (n) Median S (yrs) yr S (95% CI) 47% (33%-59%) 70% (57%-80%) Log-rank p-value = Events Median S (yrs) 3-yr S Ch.E.S.T verall Survival only (=141) 42% % Log-rank p-value* CT+ (=129) 34% unestimated 67% Hazard ratio 95% CI p-value** 0.63 (0.42, 0.93) Patients at risk at years only: CT+: * unadjusted treatment p-value **global model p-value 5
6 Meta-analyses on neoadjuvant therapy dvantages of Induction Therapy verall survival Berghmans Lung Ca 2005, 49,13-23 Huang PSC 2005; 23 bstr # RCT s =590 8 RCT s =1965 HR 0.66 (CI ) in favor of neoadjuvant chemo HR 0.68 (CI ) Higher quality trials HR 0.80 (CI ) Earlier elimination of micrometastatic disease improved survival Chemotherapy better tolerated before major surgery than after Possible downstaging of 2 disease Burdett JT 2006, 1: RCT s =988 5yr S 6% HR 0.82 (CI ) P=0.02 ssessment of chemosensitivity eoadjuvant Trials djuvant Trials Chemotherapy delivery Cisplatin dose intensity Betticher JC 2003;21 IT Lancet nc 2006;7 # of chemotherapy cycles 95.6 Depierre JC 2002;20 Rosell EJM1994; Scagliotti SC JBR10 EJM 2005;352 CLGB SC % 2 preop cycles 84% 2 postop cycles 100% of 3 preopcycles 85% 3 preop cycles 58% of 3 or more cycles 55% 4cycles at full dose Better patient tolerability of chemotherapy in pre-op rather than post-op dvantages of Induction Therapy Earlier elimination of micrometastatic disease improved survival Chemotherapy better tolerated before major surgery than after Downstaging of 2 disease survival ssessment of chemosensitivity 6
7 Median survival by L status at time of surgery in III 2 SCLC Study pcr S0139 lbain PSC 2005,23 #7014 ERTC Van Meerbeeck PSC 2005,23# mo 26 mo 26mo 40mo eoadjuvant chemotherapy and impact on type of surgery Betticher JC 2003, 21: 1752 R 35mo 16mo R Downstaging of mediastinal lymph nodes at time of surgery improves survival!! Pre-op chemo does not increase surgical complications or pneumonectomy rates Conclusions S9900 LU22/VLT R0 resection Pneumonectomy Lobectomy Surgical mortality R0 resection Pneumonectomy Lobectomy Surgical Morbidity 84% 68% chemo 84% 68% 2.5% 4.5% 79% 28% 50% 81% 23% 56% 43% 38% eoadjuvant chemotherapy is a promising modality to improve outcomes in early lung cancer Results are blunted by early closure of clinical trials Downstaging of mediastinal lymph nodes with induction therapy improves survival Better tolerability of chemotherapy preoperatively Induction chemotherapy does not increase surgical morbidity and does not decrease rate of pneumonectomies 7
8 ngoing trials eoadjuvant or djuvant chemotherapy Targeted agents Chemotherapy or chemoradiation eoadjuvant or djuvant chemotherapy IB - III TC X3 TC x 3 T : Paclitaxel 200mg/m2 C:Carboplatin UC 6 Q 3 weeks TCH Trial (Spain) eodjuvant Taxol Carboplatin Hope trial ngoing trials Targeted agents eoadjuvant Chemo vs chemoradiation in 2 disease- RTG 0412 Cis / Doc / bevacizumab surgery Cis / Doc / erlotinib surgery Pazopanib surgery IB-III IB-III ever or <15pk yr I R D M I Z E Cisplatin 75mg/m2 D1,22 Docetaxel 75mg/m2 D1,22 Cisplatin 50mg/m2 D1,8,22,29 Docetaxel 20mg/m2 D1, 8,15,22,29 TRT 50.4Gy o PD Consolidation: Docetaxel 75mg/m2 D1, 22, 43 Stratification L levels: 1vs 2 odal involvement: Micro vs clinical T stage: T1 vs T2/3 Primary objectives: S Secondary: PFS, ERCC1, XRCC1,serum proteomics, Post treatment PET 8
9 eoadjuvant Chemo vs chemoradiation in 2 disease- Korea R D M I Z E Cisplatin 40mg/m2 D1,8 Taxol 90 mg/m2 D1,8 X2 cycles Cisplatin 40mg/m2 D1,8 Taxol 90 mg/m2 D1,8 X2 cycles TRT 45Gy 25Fx Cisplatin 40mg/m2 D1,8 Taxol 90 mg/m2 D1,8 X2 cycles Primary objectives: Time to recurrence VEMBER Lung Cancer wareness Month Secondary: S pcr 9
NSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More information11/21/2009. Early Stage. Stage III. From Mountain: Chest, 1997
Combined odality egimens in Locally dvanced SCLC: Current Status and Future irections Primo. Lara, Jr, Professor of edicine University of California avis Cancer Center arly Stage Stage Five-Year Survival
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationThe 7th Edition of TNM in Lung Cancer.
10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationState of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
ESMO Preceptorship Programme NSCLC Singapore 13 14 dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationSurgery for early stage NSCLC
1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationRole of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City
Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationMediastinal Staging. Samer Kanaan, M.D.
Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationThe surgeon: new surgical aproaches
The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationVATS after induction therapy: Effective and Beneficial Tips on Strategy
VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationAccording to the current International Union
Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationAlicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationCharles Mulligan, MD, FACS, FCCP 26 March 2015
Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 11 APRIL 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the University of Texas M. D. Anderson Cancer Center, Houston, TX; Puget Sound Cancer Consortium, Swedish
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationPost-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer
Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationAn Update: Lung Cancer
An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationLung Cancer: Determining Resectability
Lung Cancer: Determining Resectability Leslie E. Quint lequint@umich.edu No disclosures Lung Cancer: Determining Resectability AIM: Review imaging features that suggest resectability / unresectability
More informationInsights into Thymic Epithelial Tumors: Radiation Therapy
Insights into Thymic Epithelial Tumors: Radiation Therapy Charles R. Thomas, MD Professor and Chairman, Department of Radiation Medicine Professor, Department of Medicine, Division of Hematology/Medical
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationSurgical Approaches to Locally Advanced NSCLC. Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX
Surgical Approaches to Locally Advanced NSCLC Kemp H. Kernstine, MD, PhD Professor and Chairman UT Southwestern Medical Center Dallas, TX Keep it real simple. Do one thing and do it the best you can. -Harry
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationCooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D.
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery, Kanagawa
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationNEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G.
Slide 1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery,
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationHISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018
30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective
More informationsurgical approach for resectable NSCLC
surgical approach for resectable NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France 1933 Graham EA, Singer JJ.
More informationM D..,., M. M P.. P H., H, F. F A.. A C..S..
Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical
More information